This report details the blood concentration of drugs found in motorists suspected of driving under the influence of drugs from 2010 to 2012 in England and Wales. This study was carried out as new legislation has come into place, setting fixed blood concentration limits for drugs in motorists. These include a cannabis (Δ9-THC) blood concentration of 2 µg/L, amphetamine 250 µg/L, benzoylecgonine (BZE) 50 µg/L, cocaine 10 µg/L, 6-monoacetylmorphine 5 µg/L, morphine 80 µg/L, diazepam 550 µg/L and methadone 500 µg/L. Samples were screened for opiates, methadone, benzodiazepines, cannabinoids, cocaine, amphetamines and methamphetamine. Cannabinoids were the most prevalent drug group (29.7%) followed by benzodiazepines (22.7%), opiates (18.8%), cocaine (16.3%), amphetamine (7%) and methadone (5.6%). The analytical results are compared with the new per se limits to give a reference of drug concentrations prior to this legislation coming into effect. Our studies show that 64.9% of the cannabis samples, 59.1% of the cocaine samples and 94.6% of the BZE samples would be above the new per se limits set under Section 5a of the Road Traffic Act. In contrast, the medicinal drugs such as benzodiazepines and opiates (morphine) were predominantly detected at concentrations below the new per se limit. Given its medical applications, amphetamines appear to have been grouped with the medicinal type drugs, with our data showing that 25.2% of the amphetamine positive samples would exceed the new specified limit. These data show that samples containing medicinal and prescription drugs are likely to be detected below the new legal limits, while illicit drugs were typically found at concentrations above the new specified limits.
Introduction
Alcohol, licit and illicit drug use has been reported to result in impairment of driver performance and to increase the likelihood of road traffic accidents (1) (2) (3) (4) . In England and Wales, the prescribed alcohol limit is 80 mg/100 mL of blood. Prior to the 2 March 2015, no such limit existed for drugs, rather law enforcement agencies were required to prove that a motorist's ability to drive was impaired. The recently introduced legislation makes it an offence for a driver to have certain specified drugs at concentrations in blood above a specified limit (Table I) (5) . The specified drugs have been divided into two broad categories medicinal drugs and drugs of abuse. The limits for the medicinal drugs have been set at reasonably high levels using a risk threshold approach and with the intention of not dissuading patients from using their prescribed medication. The limits for the drugs of abuse have been set on a "zero tolerance" basis while making allowance for accidental exposure.
Before March 2015 drivers could be arrested for driving while unfit through drugs if a police officer had reason to believe that the motorist was under the influence of drugs, based either on the driver's performance in Field Impairment Tests (FIT) or based solely on the manner of driving. Additionally, before a blood or urine sample could be obtained for toxicological analysis, the driver had to be assessed by a Forensic Medical Examiner (FME) who was required to reach the opinion that the subject "had a condition which may be due to some drug". This requirement results in a certain amount of delay. Alongside the introduction of the new per se drug concentrations limits, a number of other changes have come into effect. Roadside screening tests for cannabis and cocaine have been type approved and motorists suspected of drug driving can be required to provide an oral fluid specimen. If the roadside screening test is positive, a motorist can be arrested without evidence of impairment and a sample of blood can be taken without the need for an FME to believe that the driver has a condition due to a drug (6, 7). Additionally, samples of blood can now be obtained by Health Care Professionals, a category that includes nurses, rather than solely by FMEs. These changes should shorten the average time between incident and sampling, consequently certain drugs are more likely to be detected at higher concentrations than previously.
A recent study in Colorado showed a significant decrease of THC concentrations in samples that were taken more than 2 hours after the incident, underlining the importance of acquiring blood samples as close as possible to the time of the incident (8) . The new per se legislation places an additional onus on the accuracy of the analytical results. Under the existing legislation, the analytical result supported the impairment evidence. Under the new per se law, the case rests solely on the analytical result. The data presented here do not include allowances for analytical uncertainty. Under the new legislation, allowances for analytical uncertainty will be made and are likely to be in the region of 20-40% (k = 3).
There have been several studies carried out on the prevalence of drink and drug driving within the UK (9-13). These studies have indicated that a high proportion of samples tested would be in excess of the new legal drug driving limits (9, (11) (12) (13) .
This study details the analysis of blood samples for the presence of drugs over a 3-year period from 2010 to 2012. We have sought to identify the most prevalent drug concentrations in motorists suspected of driving while impaired and compare these against the new prescribed limits.
Materials and methods

Blood sampling
We analyzed blood samples of suspected drug driving motorists over a 3-year period from 2010 to 2012 from a number of police forces in England and Wales. Typically, samples received at the laboratory ranged between 2 and 5 mL in volume and contained sodium fluoride as a preservative and potassium oxalate as anti-coagulant.
Preliminary screening
All blood samples from suspected drugged drivers underwent a preliminary ELISA screen. Screening analysis was carried out on samples using COZART ELISA kits and a Grifols Triturus plate reader. A four-point calibration curve (including cut-off) was run for each drug group, samples that tested positive for any of the drug groups were sent for further quantitative analysis. Further information regarding the details on this technique and the confirmation analysis can be found in Supplementary Figure 1 .
Tetrahydrocannabinol and 11-nor-9-carboxy-delta-9-tetrahydrocannabinol Tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (THC-COOH) were extracted by protein precipitation, the extracts were then passed through a High Flow Bond Elut Certify II SPE cartridges 100 mg. The Trimethylsilyl-derivative extracts were analyzed by GC-MS in selected ion monitoring (SIM) mode.
Benzodiazepines
Blood samples were treated with phosphate buffer pH 7.4 and the analytes were extracted from the buffered blood with ether. The ether extracts were taken to dryness under nitrogen and derivatized. Analysis was carried out by GC-MS in SIM mode.
Opiates, methadone and cocaine
After protein precipitation extracts were pH adjusted using phosphate buffer. Analytes were passed through Bond Elut Certify SPE cartridges. The TMS derivatives are analyzed by GC-MS in SIM mode.
Amphetamine
Blood samples were protein precipitated using acetonitrile. The supernatant was evaporated and reconstituted in a potassium hydroxide solution. Extracts were passed through a CHEM ELUT Column before derivatization with Heptafluorobutyric acid anhydride. Samples were analyzed by GC-MS in SIM mode.
Results
Drug screening of blood samples in suspected drug impaired motorists
From 2010 to 2012, 4,684 blood samples from suspected drug impaired motorists screened positive for drugs. Cannabinoids were the most commonly encountered substance, comprising 29.7% of positives, followed by benzodiazepines at 22.7%. Opiates accounted for 18.8%, cocaine and benzoylecgonine (BZE) screened positive in 16.3%. Amphetamine was detected in 7% of the blood samples, while methadone was found in 5.6% of samples ( Figure 1 ). The average time between incident and sampling for this study was 3 hours and 23 minutes (based on analysis of 232 samples from this data set). It should be noted that these results do not account for poly drug use but instead focus on a cumulative ranking of the most frequently encountered drugs from road traffic samples. Once we had established what the most common drug classes in UK motorist were, we attempted to determine their most frequent concentration ranges.
Quantitation of THC and THC-COOH in blood samples of suspected DUID motorists THC and 11-nor-9-carboxy-delta-9-tetrahydrocannabinol, or THC-COOH, were the most commonly detected analytes in suspected drugged drivers. Of 926 THC positive samples, 64.9% would be in excess of the new limit (2 μg/L). Under the new drug driving legislation, THC-COOH is not subject to a limit. Our results show that of 1,159 THC-COOH positive samples, the most prevalent concentration range was 20-40 μg/L with 30.9% of positive samples, while 21.3% were found between 40 and 60 μg/L (Table II) . Diazepam has been assigned a legal blood limit of 550 μg/L, 38.2% of samples were detected in excess of this limit.
Analysis of benzodiazepine blood concentrations in suspected drugged drivers
The new legal limit for oxazepam is 300 μg/L, our results show that only 14.7% of samples exceeded this limit. The new legal limit of temazepam is 1,000 μg/L, in this study only 5.8% of samples were above this limit.
As of yet there is no fixed legal limit for nordiazepam in England and Wales (Table III) .
Concentrations of opioids and methadone in suspected drugged drivers blood samples
Morphine and codeine are commonly found in the biological samples of heroin users, in addition to therapeutic morphine and codeine users. Synthetic opioids, such as oxycodone, oxymorphone, hydromorphone, etc., are not widely available in England and Wales and do not form part of the standard panel of drugs tested for. Of 273 morphine positive samples, only 8.1% would be above the new specified limit of 80 μg/L. To date no limit has been set for codeine, of the 110 codeine positive samples only 47.3% were found to contain a concentration >10 μg/L. Of the 210 methadone positive samples, 1.0% of these would be above the new specified limit of 500 μg/L (Table IV) .
Quantitation of cocaine and BZE in blood samples of suspected impaired drugged drivers
Cocaine and its major metabolite BZE are frequently encountered illicit drug analytes in forensic toxicology. Under the new law, drivers found with a blood concentration of cocaine >10 μg/L and or a BZE concentration >50 μg/L will be prosecuted. Of 274 cocaine positive samples, 59.1% exceeded the new legal limit. Of 551 BZE positive samples, 94.6% were found to be in excess of the new limit (Table V) .
Analysis of amphetamine concentration in blood of suspected drugged drivers
Amphetamine has historically been used as a stimulant for both recreational and therapeutic use and is part of the laboratory standard panel of drugs for routine analysis. Of the 218 amphetamine positive samples, 25.2% would be above the new specified limit of 250 μg/L (Table VI) . Methamphetamine is not widely used in England and Wales, despite testing for methamphetamine it was not found in sufficient numbers to warrant inclusion in this study. 
Discussion
This study reports the drug concentrations found in samples taken between 2010 and 2012 in England and Wales from drivers suspected of being unfit through drugs. It seeks to predict the percentage of suspected drugged drivers that would face prosecution under the recently amended Road Traffic Act. Typically blood samples were taken from drivers where there was evidence of driving impairment and the motorist screened negative for alcohol. It is hoped that the introduction of preliminary drug screening tests concurrent with the introduction of the new per se drug driving legislation will increase the detection rate of drug driving and reduce its prevalence. Cannabis was found to be the most prevalent drug detected in motorists suspected of driving while unfit through drugs. Under new legislation in England and Wales, drivers will be prosecuted if they have a blood THC concentration in excess of 2 μg/L. This limit is a "zero tolerance" policy for cannabis use rather than a "zero" limit due to the analytical difficulties associated with enforcing a 0.0000 μg/L limit and makes allowances for accidental exposure. Of note, 65% of the THC positive samples in this study would be in excess of the new legal limit. It is hoped that a reduction in the time interval between the incident and sampling, due to the use of preliminary screening test and the use of health-care professionals to take samples rather than solely FMEs, will lead to a higher THC positive rate. This increase may be offset by the need to make an allowance for analytical variation and uncertainty. This allowance is likely to be an adjustment to the analytical result in the region of 20-40% (k = 3).
After cannabis the most common drug group encountered from our screening data was benzodiazepines. This group is known to decrease psychomotor function and impair driving performance (14) .
A 2006 assessment of England and Wales FITs showed that benzodiazepines were the most commonly detected drug group in a study of 283 samples (15) , while in a 2013 study of 296 drug driving samples benzodiazepines were present in 76 samples (10) . Of the 545 diazepam positive samples in our study, 38.2% were found in excess of the new limit of 550 μg/L. The new limit for oxazepam is 300 μg/ L, only 14.7% of samples tested in our laboratory exceeded this limit. The majority of temazepam samples was also detected below the new limit with only 5.8% of samples found to be above 1,000 μg/L. These results show a common trend that is observed throughout this study, namely that the specified limits given to prescription and medicinal drugs are such that the majority of samples that screen positive are likely to be below the new per se limits. The limits for medicinal drugs have been set at higher concentrations in order to avoid dissuading prescribed users from taking their medication. Furthermore, the new legislation includes an automatic defence for motorists that can demonstrate that they are using their medications in accordance to their prescription (7) .
Under the new amended Road Traffic Act morphine, 6-AM and methadone are the only opioids with specified limits. Over a 3-year period, our lab has only encountered four 6-AM positives in 4,684 samples, of which none exceeded the new limit of 5 μg/L. This is to be expected given the short half life of this metabolite (10-25 min). Morphine is one of the oldest analgesics used for medicinal purposes and a metabolite of heroin. The effects of opioids on driving are variable (4, 16, 17) , the European DRUID study suggested that medicinal opiate users (codeine) are more likely to be involved in a road traffic collision than illicit (heroin) opiate users (9) . A previous study carried out on motorists in England and Wales showed that the mean concentration of morphine encountered was~40 μg/L (10) . The average morphine concentration in our study was found to be 34 μg/L and a median concentration of 20 μg/L. In this study, only 8.1% of morphine positive samples were above the new specified limit of 80 μg/L. Similarly, methadone was only detected above the specified limit in 1.0% of cases. These findings are largely in line with a number of European drug driving studies in the Netherlands (18), Switzerland (19) , Sweden (20) and Norway (21) where the majority of morphine positive samples was found to lie within the range of 10-70 μg/L. Under the new legislation, there is no fixed limit for codeine, while the effect of codeine on driving impairment is still unclear (22) , in this study 74.5% of codeine positive samples were <40 µg/L.
A 2009/2010 survey of drivers in England and Wales who admitted driving under the influence of illegal drugs found that cocaine was the second most commonly used drug (9) . In our study, cocaine was the fourth most prevalent drug in preliminary screening analysis. The usage of cocaine among UK drivers is well documented (9) (10) (11) 23) , an investigation of coroners and procurators samples found that of the 372 driver fatalities that were positive for drug and alcohol, cocaine was present in 5% of cases (9) . In addition, a 2011 study showed that cocaine was the most commonly detected drug and was present in 92 of 295 samples quantified for drug use (10), although it should be noted that this study did not investigate cannabis use. Under the new per se section of the Road Traffic Act, motorists will be prosecuted if they are found to have cocaine in excess of 10 µg/L and BZE over 50 µg/L (5). In this dataset, 59 .1% of motorists that tested positive for cocaine would be above the legal limit, while for BZE, 94.6% of samples were found above the new per se legal limit.
A screening study of drug use in Scottish motorist showed that amphetamine accounts for 6% of positive drug samples (23) . These results are in agreement with our findings from England and Wales where amphetamines were found in 7% of drug screened samples. Our study indicates that under the new legislation 25.2% of amphetamine positive samples would be above the specified limit of 250 µg/L.
An interesting feature of the new drug limits is the inclusion of BZE. A sample that contains both BZE and cocaine above the specified limits may be prosecuted twice following the use of a single drug. Additionally, samples that have no cocaine can still be above the threshold for BZE irrespective of impairment and time since last cocaine use. The same approach was not applied to THC and THC-COOH.
Conclusion
The results of this study provide an insight into the typical concentration ranges of drugs commonly detected in motorists in England and Wales, as well as a future reference point for the effects of new drug driving legislation on driving habits. Our results suggest that the majority of samples positive for medicinal drugs, such as benzodiazepine and opiates, will not be in excess of the new legal limits. In contrast, the majority of illicit drugs, such as cocaine and THC, was found in excess of the specified limits. Our findings also show that cannabis, benzodiazepines, opiates and cocaine are the most frequently encountered drugs in samples drivers in England and Wales.
